Search results
Recursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue S
Guru Focus· 8 hours agoRevenue: Reported at $13.8 million for Q1 2024, up from $12.1 million in Q1 2023, surpassing estimates of $12.65 million.Net Loss: Increased to $91.4 million i
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 8 hours agoArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript May 9, 2024 Arrowhead...
Earnings call: Achieve Life Sciences reports progress on cytisinicline trials By Investing.com
Investing.com· 8 hours agoAchieve Life Sciences (NASDAQ:ACHV), a clinical-stage pharmaceutical company, has made significant...
Vanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates
GuruFocus.com via Yahoo Finance· 5 hours agoThe company is also advancing its pipeline with ongoing clinical programs and upcoming new drug...
Recursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue Surpasses Estimates Amid ...
GuruFocus.com via Yahoo Finance· 7 hours agoThe Salt Lake City-based clinical stage TechBio company continues its journey to revolutionize drug discovery by integrating advanced technologies across ...
Nika Pharmaceuticals, Inc. (Nika) Acquires a Two Million USD Production Building - Nika ...
Benzinga· 8 hours agoOn May 9, 2024, NIKA acquired Nika Pharmaceuticals, Ltd.; as a result, the company became 99.99% owner of Nika Europe, Ltd, in whose capital the production ...
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
FOX 4 Kansas City· 12 hours agoCitius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development ...
Earnings call: PolyPid reports progress in D-PLEX100 trial, eyes expansion By Investing.com
Investing.com· 5 hours agoPolyPid Ltd. (NASDAQ:PYPD), a specialty pharmaceutical company, announced its first-quarter...
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug...
Digital Journal· 13 hours agoCompany” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of an Amendment Acknowledgment ...
Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.
Quartz· 3 days agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar ...